Skip to content

MDMA: all studies

Page 345 of 345: studies 3,441 to 3,446 of 3,446, newest first. Back to the MDMA overview

Research

Evidence-Based Medicine is inadequate to develop evidence-based psychedelic therapies.

Eduardo Ekman Schenberg preprint

Between April and October 2024, expert bodies in two countries reached strikingly opposite conclusions about the therapeutic use of 3,4-methylenedioxymethamphetamine (MDMA). On the one hand, the Food and Drug Administration in the USA rejected a formal New Drug Application from a specific drug sponsor, Lykos Therapeutics, for Post-Traumatic Stress Disorder (PTSD). The decision was surprising to...

Binaries, Multitudes, and Beyond: A Client-Authored Case Study in Psychedelic-Assisted Therapy, Artificial Intelligence, and Narrative Agency

Mark A. Michaels preprint

This client-authored, autoethnographic case study documents a 10-week course of collaborative therapy integrating EMDR, ketamine, MDMA, psilocybin, creative expression, and AI-assisted reflection and writing. Drawing on affect theory, mentalization, earned secure attachment, and Dabrowski's theory of positive disintegration, the paper analyzes how recognition of core affects, rupture-and-repair...

Malpractice without a Baseline: Tort Liability and the Structural Paradoxes of Psychedelic-assisted Therapy

Michael Palmieri preprint

Psychedelic-assisted therapy is advancing rapidly toward clinical legitimacy in the United States. The Food and Drug Administration has granted Breakthrough Therapy designations to psilocybin and MDMA, several states have established regulated access frameworks, and major research institutions have invested hundreds of millions of dollars in psychedelic science. Yet the legal infrastructure...

Consent Without Continuity: Psychedelic-Assisted Therapy and the Structural Failure of Informed Consent Doctrine

Michael Palmieri preprint

American informed consent doctrine rests on an unexamined premise: the stable-agent assumption—that the patient who authorizes a medical intervention and the patient who experiences its consequences share a continuous evaluative framework. Materiality doctrine presupposes this continuity; causation doctrine embeds it; capacity doctrine assumes it. For most of modern medical practice, the...

The Birth of the Psychedelic Industry: Capitalizing on the Psychedelic Renaissance

Minsu Yoo, Sofia Sakopoulos

Recent scientific findings spanning the past two decades have prompted a reevaluation of psychedelics, including psilocybin, LSD, and MDMA, as potent tools for mental health treatment. While these substances were historically associated with countercultural movements, concerns and excitement arise as they become commercialized. Based on in-depth interviews of relevant stakeholders of the scene,...

Psychedelics Use and the Risk of Reduced Formal Mental Health Care

Research Square Sean M. Viña preprint

Abstract Background: Due to increasing cultural and legal acceptance of psychedelics, there is a need to understand their potential influence on formal mental health care. This paper examines the connection between psychedelics, distress, and treatment utilization. Are psychedelic users less likely to use formal mental health care? Methods This study tests the relationship between psychedelics...